Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

103 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Estimated glomerular filtration rate and albuminuria are independent predictors of cardiovascular events and death in type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.
Drury PL, Ting R, Zannino D, Ehnholm C, Flack J, Whiting M, Fassett R, Ansquer JC, Dixon P, Davis TM, Pardy C, Colman P, Keech A. Drury PL, et al. Among authors: zannino d. Diabetologia. 2011 Jan;54(1):32-43. doi: 10.1007/s00125-010-1854-1. Epub 2010 Jul 30. Diabetologia. 2011. PMID: 20668832
Incidence and predictors of silent myocardial infarction in type 2 diabetes and the effect of fenofibrate: an analysis from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.
Burgess DC, Hunt D, Li L, Zannino D, Williamson E, Davis TM, Laakso M, Kesäniemi YA, Zhang J, Sy RW, Lehto S, Mann S, Keech AC. Burgess DC, et al. Among authors: zannino d. Eur Heart J. 2010 Jan;31(1):92-9. doi: 10.1093/eurheartj/ehp377. Epub 2009 Sep 29. Eur Heart J. 2010. PMID: 19797259 Clinical Trial.
Favourable effects of fenofibrate on lipids and cardiovascular disease in women with type 2 diabetes: results from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.
d'Emden MC, Jenkins AJ, Li L, Zannino D, Mann KP, Best JD, Stuckey BG, Park K, Saltevo J, Keech AC; FIELD Study Investigators. d'Emden MC, et al. Among authors: zannino d. Diabetologia. 2014 Nov;57(11):2296-303. doi: 10.1007/s00125-014-3344-3. Epub 2014 Aug 23. Diabetologia. 2014. PMID: 25149070 Clinical Trial.
Relationships of HDL cholesterol, ApoA-I, and ApoA-II with homocysteine and creatinine in patients with type 2 diabetes treated with fenofibrate.
Taskinen MR, Sullivan DR, Ehnholm C, Whiting M, Zannino D, Simes RJ, Keech AC, Barter PJ; FIELD study investigators. Taskinen MR, et al. Among authors: zannino d. Arterioscler Thromb Vasc Biol. 2009 Jun;29(6):950-5. doi: 10.1161/ATVBAHA.108.178228. Epub 2009 Mar 26. Arterioscler Thromb Vasc Biol. 2009. PMID: 19325138 Clinical Trial.
Erratum to: Favourable effects of fenofibrate on lipids and cardiovascular disease in women with type 2 diabetes: results from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.
d'Emden MC, Jenkins AJ, Li L, Zannino D, Mann KP, Best JD, Stuckey BG, Park K, Saltevo J, Keech AC; FIELD Study Investigators. d'Emden MC, et al. Among authors: zannino d. Diabetologia. 2015 Sep;58(9):2200. doi: 10.1007/s00125-015-3693-6. Diabetologia. 2015. PMID: 26186882 Free article. No abstract available.
Exercise Intolerance, Benefits, and Prescription for People Living With a Fontan Circulation: The Fontan Fitness Intervention Trial (F-FIT)-Rationale and Design.
Tran DL, Gibson H, Maiorana AJ, Verrall CE, Baker DW, Clode M, Lubans DR, Zannino D, Bullock A, Ferrie S, Briody J, Simm P, Wijesekera V, D'Almeida M, Gosbell SE, Davis GM, Weintraub R, Keech AC, Puranik R, Ugander M, Justo R, Zentner D, Majumdar A, Grigg L, Coombes JS, d'Udekem Y, Morris NR, Ayer J, Celermajer DS, Cordina R. Tran DL, et al. Among authors: d udekem y, zannino d, d almeida m. Front Pediatr. 2022 Jan 6;9:799125. doi: 10.3389/fped.2021.799125. eCollection 2021. Front Pediatr. 2022. PMID: 35071139 Free PMC article. Review.
Hepatic and renal end-organ damage in the Fontan circulation: A report from the Australian and New Zealand Fontan Registry.
Wilson TG, d'Udekem Y, Winlaw DS, Cordina RL, Celermajer DS, Wheaton GR, Bullock A, Gentles TL, Weintraub RG, Justo RN, Grigg LE, Radford DJ, Hardikar W, Cheung M, Cain TM, Rao P, Alexander SI, Ayer J, Verrall C, Du Plessis K, Chapman J, Rice K, Barry J, Zannino D, Iyengar AJ; Australian and New Zealand Fontan Registry. Wilson TG, et al. Among authors: d udekem y, zannino d. Int J Cardiol. 2018 Dec 15;273:100-107. doi: 10.1016/j.ijcard.2018.07.118. Epub 2018 Jul 25. Int J Cardiol. 2018. PMID: 30060970
Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer.
Stockler MR, Harvey VJ, Francis PA, Byrne MJ, Ackland SP, Fitzharris B, Van Hazel G, Wilcken NR, Grimison PS, Nowak AK, Gainford MC, Fong A, Paksec L, Sourjina T, Zannino D, Gebski V, Simes RJ, Forbes JF, Coates AS. Stockler MR, et al. Among authors: zannino d. J Clin Oncol. 2011 Dec 1;29(34):4498-504. doi: 10.1200/JCO.2010.33.9101. Epub 2011 Oct 24. J Clin Oncol. 2011. PMID: 22025143 Clinical Trial.
Neoadjuvant chemotherapy with sequential anthracycline-docetaxel with gemcitabine for large operable or locally advanced breast cancer: ANZ 0502 (NeoGem).
McCarthy N, Boyle F, Zdenkowski N, Bull J, Leong E, Simpson A, Kannourakis G, Francis PA, Chirgwin J, Abdi E, Gebski V, Veillard AS, Zannino D, Wilcken N, Reaby L, Lindsay DF, Badger HD, Forbes JF; Australia and New Zealand Breast Cancer Trials Group. McCarthy N, et al. Among authors: zannino d. Breast. 2014 Apr;23(2):142-51. doi: 10.1016/j.breast.2013.12.001. Epub 2014 Jan 3. Breast. 2014. PMID: 24393617 Free article. Clinical Trial.
103 results